Use of Ascorbic Acid in Patients With COVID 19
1 other identifier
interventional
500
1 country
1
Brief Summary
Different studies showed that ascorbic acid (vitaminC) positively affects the development and maturation of T-lymphocytes, in particular NK (natural Killer) cells involved in the immune response to viral agents. It also contributes to the inhibition of ROS production and to the remodulation of the cytokine network typical of systemic inflammatory syndrome. Recent studies have also demonstrated the effectiveness of vitamin C administration in terms of reducing mortality, in patients with sepsis hospitalized in intensive care wards. Given this background, in the light of the current COVID-19 emergency, since the investigators cannot carry out a randomized controlled trial, it is their intention to conduct a study in the cohort of hospitalized patients with covid-19 pneumonia, administering 10 gr of vitamin C intravenously in addition to conventional therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 13, 2020
CompletedFirst Submitted
Initial submission to the registry
March 18, 2020
CompletedFirst Posted
Study publicly available on registry
March 26, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 13, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 13, 2021
CompletedMarch 26, 2020
March 1, 2020
1 year
March 18, 2020
March 24, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
In-hospital mortality
Change of hospital mortality
72 hours
Secondary Outcomes (6)
PCR levels
72 hours
Lactate clearance
72 hours
Hospital stay
72 hours
Symptoms
72 hours
Positive swab
72 hours
- +1 more secondary outcomes
Study Arms (1)
Patients with COVID-19 pneumonia
EXPERIMENTALConsecutive patients with COVID-19 pneumonia admitted to ARNAS Civico-Di Cristina-Benfratelli, Palermo
Interventions
10 gr of vitamin C intravenously in addition to conventional therapy.
Eligibility Criteria
You may qualify if:
- In case of doubt of interstitial pneumonia with indications for intubation
- Positive swab test of SARS-CoV-2
- Interstitial pneumonia
- Signature of informed consent
You may not qualify if:
- Unsigned informed consent
- Negative swab test of SARS-CoV-2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
A.R.N.A.S. Civico - Di Cristina - Benfratelli
Palermo, 90127, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 18, 2020
First Posted
March 26, 2020
Study Start
March 13, 2020
Primary Completion
March 13, 2021
Study Completion
March 13, 2021
Last Updated
March 26, 2020
Record last verified: 2020-03
Data Sharing
- IPD Sharing
- Will not share